Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial
https://doi.org/10.15829/1728-8800-2022-3196
About the Author
I. S. Yavelov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
References
1. Leentjens J, van Haaps TF, Wessels PF, et al. COVID-19associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8(7):e524-33. doi:10.1016/S2352-3026(21)00105-8.
2. Barrett TJ, Cornwell M, Myndzar K, et al. Platelets amplify endotheliopathy in COVID-19. Sci Adv. 2021;7(37):eabh2434. doi:10.1126/sciadv.abh2434.
3. Martha JW, Pranata R, Lim MA, et al. Active prescription of lowdose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates. Int J Infect Dis. 2021;108:6-12. doi:10.1016/j.ijid.2021.05.016.
4. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. Lancet. 2022;399(10320):143-151. doi:10.1016/S0140-6736(21)01825-0.
5. Berger JS, Kornblith LZ, Gong MN, et al., for the ACTIV-4a Investigators. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19. A Randomized Clinical Trial. JAMA. 2022;327:227-36. doi:10.1001/jama.2021.23605.
Review
For citations:
Yavelov I.S. Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial. Cardiovascular Therapy and Prevention. 2022;21(2):3196. https://doi.org/10.15829/1728-8800-2022-3196
Views:
788
Email this article 
